The DNPEP Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human SK-HEP-1 liver adenocarcinoma line. This model provides targeted disruption of DNPEP, encoding a zinc-dependent aminopeptidase that cleaves N-terminal aspartate and glutamate residues from peptides. The polyclonal product, comprising a heterogeneous collection of gene-edited alleles, avoids clonal artifacts and offers a robust system for functional studies of DNPEP in hepatic cancer biology.
SK-HEP-1 cells were isolated from ascites of a 52-year-old male patient with liver adenocarcinoma. They exhibit dual hepatic epithelial and endothelial-like characteristics, making them a valuable model for hepatocellular carcinoma research, particularly in tumor?Cmicroenvironment interactions and vascular mimicry.
DNPEP participates in the renin-angiotensin system and glutathione metabolism by hydrolyzing acidic N-terminal residues from peptides. Its enzymatic activity requires a zinc ion cofactor and is regulated by Sp1 transcription factor and Nrf2-mediated oxidative stress responses. The enzyme degrades angiotensin II, a major vasoactive peptide, thereby influencing signaling through the angiotensin II type 1 receptor. Other substrates include cholecystokinin-8 and peptides involved in hormone processing. Pathway components such as angiotensinogen, renin, angiotensin-converting enzyme, and glutamate cysteine ligase interconnect with DNPEP-dependent peptide turnover and cellular redox control.
In the SK-HEP-1 liver adenocarcinoma context, DNPEP knockout allows researchers to dissect its roles in tumor progression, peptide hormone regulation, and metabolic adaptation. Loss of DNPEP function may impact angiotensin II levels, affecting cell proliferation, migration, and intracellular signaling cascades linked to hypertension and hepatocellular carcinoma. The endothelial-like properties of SK-HEP-1 further permit investigation of DNPEP in vascular mimicry and angiogenic processes, providing a comprehensive platform to explore aminopeptidase contributions to hepatic oncogenesis.
Applications include western blotting, RT-qPCR, and aminopeptidase activity assays for knockout validation, along with angiotensin II degradation assays for substrate specificity. Functional studies employ cell proliferation, migration, and phospho-ERK/STAT3 signaling analyses to examine downstream effects. This model is particularly suited for investigating DNPEP function in hepatocellular carcinoma, peptide hormone processing in liver cancer, and the hepatic tumor microenvironment. For more information, contact Ascent Research.
